While the lack of standard high-throughput screening methods for specific GRP78 inhibitors could have hampered past progress for their identification, the emergence of AI/machine learning in the structural characterization of therapeutic targets in cancer (104) could vastly accelerate the discovery, evaluation, and optimization of small-molecule clinical candidates targeting GRP78 itself or its interaction with specific binding partners. The gene discussed is HSPA5; the disease is cancer.